Drugs in ATC Class S01AX

Up to Top Level ATC Classes

Up to S - Sensory organs

Up to S01 - OPHTHALMOLOGICALS

Up to S01A - ANTIINFECTIVES

Drugs in ATC Class: S01AX - Other antiinfectives

Tradename	Generic Name
AVAGARD	alcohol; chlorhexidine gluconate
CHLORHEXIDINE GLUCONATE	chlorhexidine gluconate
EXIDINE	chlorhexidine gluconate
READYPREP CHG	chlorhexidine gluconate

S01AX Market Analysis and Financial Projection

The market dynamics and patent landscape for ATC Class S01AX (Other Antiinfectives) reflect a specialized segment within ophthalmological treatments, driven by innovation in drug formulations and addressing rising global demand for ocular anti-infective therapies.

---

Market Dynamics

Global Growth Drivers

The global anti-infectives market is projected to grow from $138.8 billion in 2024 to $180 billion by 2033, with a CAGR of 2.93% [3]. For S01AX-specific therapies, growth is fueled by:

• Increasing incidence of eye infections: Conditions like conjunctivitis, uveitis, and postoperative infections drive demand [14].
• Advancements in drug formulations: Novel excipients (e.g., Poloxamer 407) enhance stability and patient comfort in combination therapies (antibiotics + corticosteroids) [13].
• Shift toward sustained-release products: Injectable formulations (e.g., Dropless Therapy®) reduce reliance on topical eye drops, improving compliance [10][13].

Market Segmentation

• By Product Type: Dominated by chlorhexidine (used in antiseptic formulations [2][11]) and resorcinol (for acne/dermatitis [6]).
• By Region: North America leads due to advanced healthcare infrastructure, while Asia-Pacific shows rapid growth due to rising infection rates [3][14].

---

Patent Landscape

Key Innovations

1. Combination Therapies:

   • Patents covering antibiotic + steroid formulations (e.g., dexamethasone with moxifloxacin) use Poloxamer 407 for enhanced stability, extending IP protection to 2034 in Australia and 33 other countries [10][13].
   • Recce Pharmaceuticals’ synthetic anti-infectives (RECCE® 327/529) received a Chinese patent until 2035, targeting bacterial infections [4].

2. Novel Delivery Systems:

   • Imprimis Pharmaceuticals’ Dropless Therapy® (intraocular antibacterial/anti-inflammatory agents) secured patents for formulations reducing postoperative medication burden [10].

3. Expanding Applications:

   • Roflumilast (a PDE4 inhibitor) is patented for ocular inflammatory diseases, offering anti-inflammatory benefits with fewer side effects [5].

Competitive Outlook

• Major Players: Allergan, Bayer, Genentech, and Valeant dominate the ophthalmic anti-infective market [14].
• Patent Expirations: Key patents (e.g., chlorhexidine gluconate) are nearing expiry, opening avenues for generics [11].

---

Challenges and Opportunities

• Regulatory Hurdles: Stringent requirements for novel excipients delay market entry [13].
• Regional Disparities: Limited awareness and healthcare access in developing regions hinder growth [14].
• R&D Investments: Rising focus on broad-spectrum agents (e.g., Recce’s polymers [4]) and non-antibiotic antiseptics (e.g., sodium propionate [16]) to combat resistance.

---

Key Takeaways

1. The S01AX class is pivotal in treating ocular infections, with chlorhexidine and resorcinol as cornerstones.
2. Patent activity centers on combination therapies and sustained-release technologies, ensuring prolonged market exclusivity.
3. Emerging markets and innovative drug delivery systems present untapped growth potential.

---

"Protecting these valuable assets is critical, and the issuance of this key patent not only strengthens our IP portfolio but sets a strong precedent that our core technology is truly novel and innovative."
– Mark L. Baum, CEO of Imprimis Pharmaceuticals [10].

References

1. https://www.iqvia.com/-/media/iqvia/pdfs/belgium/sales-trends/2020/may-belgian-reg-med-best.pdf
2. https://go.drugbank.com/drugs/DB00878
3. https://www.imarcgroup.com/anti-infectives-market
4. https://www.biospace.com/recce-pharmaceuticals-granted-new-patent-in-china-for-recce-anti-infectives
5. https://patents.justia.com/patent/20230090417
6. https://go.drugbank.com/drugs/DB11085
7. https://en.wikipedia.org/wiki/ATC_code_S01
8. https://prediction.charite.de/subpages/tree.php
9. https://atcddd.fhi.no/atc_ddd_index/?code=S01XA&showdescription=yes
10. https://investors.harrow.com/news-releases/news-release-details/imprimis-pharmaceuticals-secures-first-key-composition-patent
11. https://www.drugpatentwatch.com/p/atc-class/S01AX
12. https://atcddd.fhi.no/atc_ddd_index/?code=S01XA01
13. https://www.ophthalmologytimes.com/view/patents-granted-for-combination-antibiotics-with-steroids-as-topical-eye-drops
14. https://www.biospace.com/ophthalmic-anti-infective-market-increase-in-incidence-of-eye-infection-to-drive-the-market
15. https://pubchem.ncbi.nlm.nih.gov/compound/Nitrofurazone
16. https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-propionate